Cov hlwb qog nqaij hlav muaj cov khoom uas muaj hluav taws xob them, yog li ntawd lawv thiaj li raug cuam tshuam los ntawm cov teb hluav taws xob. Kev siv cov teb hluav taws xob hloov pauv (TTFields) rau cov qog nqaij hlav khov kho xaiv thiab cuam tshuam mitosis ntawm ntau theem hauv kev faib cov hlwb qog nqaij hlav, txhim kho kev tiv thaiv kab mob qog nqaij hlav thiab txo qis kev puas tsuaj DNA ua rau cov hlwb qog nqaij hlav tuag. Kev sim tshuaj kho mob tau qhia tias kev kho mob TTFields ua rau muaj kev ciaj sia ntawm glioblastoma, mesothelioma thiab cov mob qog nqaij hlav ntsws uas tsis yog me me uas kis mus rau lwm qhov, yog li kev kho mob TTFields tau pom zoo rau kev kho mob ntawm cov mob qog nqaij hlav no ua ntej. Tam sim no, thaum Lub Ob Hlis 12, 2026, raws li cov txiaj ntsig los ntawm kev sim tshuaj kho mob tsis ntev los no, FDA tau pom zoo rau kev kho mob TTFields rau mob qog nqaij hlav pancreatic uas tau nce qib hauv zos. Qhov no tseem ceeb heev vim tias kev tswj hwm kev kho mob ntawm mob qog nqaij hlav pancreatic yog qhov nyuaj vim tias kev kwv yees tsis zoo thiab tus nqi ciaj sia tsawg.
Cov teb hluav taws xob hloov pauv, hu ua Tumour Treating Fields (TTFields), xa los ntawm lub cuab yeej tsim hluav taws xob uas tsis muaj kev cuam tshuam tau raug pom zoo rau kev kho mob qog nqaij hlav pancreatic hauv cov neeg laus.
Optune Pax, lub cuab yeej nqa tau uas tau tsim los ntawm Novocure yog tau txais kev pom zoo rau kev kho mob qog nqaij hlav pancreatic hauv zos rau hnub tim 12 Lub Ob Hlis 2026 los ntawm FDA raws li cov txiaj ntsig ntawm theem 3 kev sim tshuaj uas qhia tau tias kev ntxiv TTFields rau tus qauv kev kho mob chemotherapy gemcitabine thiab nab-paclitaxel (GnP) tau txhim kho kev ciaj sia tag nrho los ntawm kwv yees li ob lub hlis piv rau GnP ib leeg. Lub cuab yeej tau txais Breakthrough Device ua ntej thaum Lub Kaum Ob Hlis 2024.
Kev kho mob qog nqaij hlav (TTFields) yog kev kho mob qog nqaij hlav uas tsis yog kev phais. Nws siv lub zog hluav taws xob tshwj xeeb xws li 100 kHz txog 300 kHz, uas cuam tshuam kev faib cov qe ntshav qog nqaij hlav sai thiab ua rau cov qe ntshav tuag thaum cov qe ntshav noj qab nyob zoo feem ntau tsis raug cuam tshuam. Nws tau txais kev pom zoo los ntawm cov neeg mob thiab pom tias ua rau cov neeg mob uas muaj qog nqaij hlav muaj sia nyob zoo dua.
TTFields twb tau txais kev pom zoo lawm kev kho mob ntawm cov mob glioblastoma multiforme (GBM) uas nyuam qhuav kuaj pom thiab rov tshwm sim dua, mob malignant pleural mesothelioma (MPM) thiab mob qog nqaij hlav ntsws uas tsis yog me me uas kis mus rau lwm qhov (metastatic non-small cell lung cancer). Mob qog nqaij hlav pancreatic uas kis mus rau lwm qhov yog qhov tshiab tshaj plaws hauv daim ntawv teev npe.
Mob qog nqaij hlav pancreatic yog ib yam kab mob hnyav heev uas muaj kev kwv yees tsis zoo thiab muaj feem yuav ciaj sia tsawg. Nws yog ib qho ntawm cov mob qog nqaij hlav uas nyuaj kho tshaj plaws. Kev pom zoo ntawm TTFields rau Theem III mob qog nqaij hlav pancreatic hauv zos muab kev xaiv kho mob tshiab rau cov neeg mob.
***
References:
- Xov Xwm Tshaj Tawm ntawm FDA - FDA Pom Zoo Rau Cov Khoom Siv Kho Mob Cancer Pancreatic Ua Ntej. Tshaj tawm rau hnub tim 12 Lub Ob Hlis 2026. Muaj nyob rau ntawm https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer
- Babiker HM thiab al 2025. Kev Kho Mob Qog Nrog Gemcitabine thiab Nab-Paclitaxel rau Kev Kho Mob Pancreatic Adenocarcinoma Hauv Zos: Kev Tshawb Fawb Randomized, Open-Label, Pivotal Phase III PANOVA-3. J Clin Oncol 43, 2350-2360 (2025) Ntim 43, Naj Npawb 21. DOI: https://doi.org/10.1200/JCO-25-00746
- Cov Nyhuv ntawm Cov Chaw Kho Mob Qog (TTFields, 150 kHz) ua Kev Kho Mob Pem Hauv Ntej ntawm Cov Mob Pancreatic Adenocarcinoma Hauv Zos Ua Ke Nrog Gemcitabine thiab Nab-paclitaxel (PANOVA-3). NCT03377491. Muaj nyob ntawm https://clinicaltrials.gov/study/NCT03377491?tab=study
- Serventi JN thiab Newton HB, 2025. Cov Kev Kho Mob Qog: Ib Txoj Kev Kho Mob Tshiab rau Glioblastoma thiab Lwm Cov Qog Khoom. JADPRO Ntim 16, Naj Npawb 5 (Cuaj Hlis/Lub Kaum Hli 2025). DOI: https://doi.org/10.6004/jadpro.2025.16.5.3
- Li, Xing et al 2023. Kev tshuaj xyuas txog cov teb kho mob qog (TTFields): kev nce qib hauv kev siv kho mob thiab kev nkag siab txog cov txheej txheem. Radiology thiab Oncology Ntim 57 (2023): Qhov Teeb Meem 3 (Cuaj Hlis 2023), DOI: https://doi.org/10.2478/raon-2023-0044
- Shams S. thiab Patel CB, 2022. Cov txheej txheem tiv thaiv kab mob qog noj ntshav ntawm kev ua haujlwm ntawm kev kho mob hloov pauv hluav taws xob (cov teb kho mob qog noj ntshav [TTFields]). Journal of Molecular Cell Biology, Ntim 14, Qhov Teeb Meem 8, Lub Yim Hli 2022, mjac047. DOI: https://doi.org/10.1093/jmcb/mjac047
***
TTFields Txoj Haujlwm Ua Haujlwm
 to solid tumours selectively target and disrupt mitosis at different stages in division of cancer cells, enhance antitumor immunity and downregulate DNA damage response leading to death of cancer cells. Clinical trials have shown that TTFields therapy enhances survival rates of glioblastoma, mesothelioma and metastatic non–small cell lung cancer cases hence TTFields therapy was approved for the treatment of these cancer cases earlier. Now, on 12 February 2026, based on the results from a recent clinical trial, FDA has approved TTFields therapy for locally advanced pancreatic cancer as well. This is significant given clinical management of pancreatic cancer is challenging in view of poor prognosis and low survival rate.){kind=link}